Rhythm Pharmaceuticals In... (RYTM)
Bid | 95.99 |
Market Cap | 6.39B |
Revenue (ttm) | 156.29M |
Net Income (ttm) | -183.06M |
EPS (ttm) | -3.01 |
PE Ratio (ttm) | -31.97 |
Forward PE | -49.89 |
Analyst | Strong Buy |
Ask | 97.91 |
Volume | 488,722 |
Avg. Volume (20D) | 712,830 |
Open | 98.17 |
Previous Close | 97.92 |
Day's Range | 96.15 - 98.40 |
52-Week Range | 45.91 - 106.52 |
Beta | 2.24 |
About RYTM
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for RYTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

1 month ago · seekingalpha.com
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call TranscriptRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David...

2 months ago · seekingalpha.com
Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity MarketRhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market...

2 months ago · seekingalpha.com
Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent ProspectsI maintain my Buy rating on Rhythm Pharmaceuticals due to its leadership in rare genetic obesity treatments. The company's innovative therapies address significant unmet needs, supporting long-term gr...